Marker Therapeutics Announces CMO Departure, Executive Compensation Details
Ticker: MRKR · Form: 8-K · Filed: Jan 30, 2025 · CIK: 1094038
| Field | Detail |
|---|---|
| Company | Marker Therapeutics, Inc. (MRKR) |
| Form Type | 8-K |
| Filed Date | Jan 30, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-departure, compensation
TL;DR
CMO out, exec pay details out. Marker Therapeutics files 8-K.
AI Summary
On January 24, 2025, Marker Therapeutics, Inc. announced the departure of Dr. Juan F. Vera from his role as Chief Medical Officer. The company also disclosed compensatory arrangements for its named executive officers, including base salary, potential bonuses, and equity awards, effective January 24, 2025.
Why It Matters
The departure of a Chief Medical Officer can signal strategic shifts or challenges in drug development, while details on executive compensation provide insight into the company's financial planning and incentives for leadership.
Risk Assessment
Risk Level: medium — The departure of a key executive like the CMO can introduce uncertainty regarding the company's strategic direction and drug development pipeline.
Key Players & Entities
- Marker Therapeutics, Inc. (company) — Registrant
- Dr. Juan F. Vera (person) — Departing Chief Medical Officer
- January 24, 2025 (date) — Effective date of events
FAQ
Who has departed from Marker Therapeutics, Inc.?
Dr. Juan F. Vera has departed from his role as Chief Medical Officer.
What is the effective date of the reported events?
The earliest event reported is effective as of January 24, 2025.
What other information is disclosed in this 8-K filing?
The filing also discloses compensatory arrangements for certain officers of the company.
What was Marker Therapeutics, Inc.'s former name?
Marker Therapeutics, Inc. was formerly known as TAPIMMUNE INC. and GENEMAX CORP.
In which state was Marker Therapeutics, Inc. incorporated?
Marker Therapeutics, Inc. was incorporated in Delaware.
Filing Stats: 411 words · 2 min read · ~1 pages · Grade level 11.7 · Accepted 2025-01-30 16:05:26
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share MRKR The Nasdaq Stock Mar
Filing Documents
- tm254924d1_8k.htm (8-K) — 23KB
- 0001104659-25-007574.txt ( ) — 193KB
- mrkr-20250124.xsd (EX-101.SCH) — 3KB
- mrkr-20250124_lab.xml (EX-101.LAB) — 33KB
- mrkr-20250124_pre.xml (EX-101.PRE) — 22KB
- tm254924d1_8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Marker Therapeutics, Inc. Dated: January 30, 2025 By: /s/ Juan Vera Juan Vera President and Chief Executive Officer